ALFA Concalls
Every earnings call, live and summarised
Earnings calls
Every Sahajanand Medical Technologies earnings call we streamed: the live audio and our summary of what management said.
Record Q2 FY27: revenue up 24.7% to about ₹373 Cr, EBITDA up 36.6%, margin 17.6%. Reported H1 PAT up only 7.5% due to a prior-year one-off tax credit; ex-it about 39%. Gross margin fell 170 bps on traded-product mix.
Record Q2 FY27: revenue up 24.7% to about ₹373 Cr, EBITDA up 36.6%, margin 17.6%. Reported H1 PAT up only 7.5% due to a prior-year one-off tax credit; ex-it about 39%. Gross margin fell 170 bps on traded-product mix.
EBITDA margin +150–200 bps yearly; ~20% by FY29. Constant-currency revenue growth mid-to-high teens; capex ~₹70 Cr FY27–28.
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.